Xenon Pharmaceuticals Inc. (XENE) Stock Score, Valuation & Financial Research

Xenon Pharmaceuticals Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for XENE

Xenon Pharmaceuticals Inc. does not currently have a complete Wall Street Score. The stored market price is USD 35.90. These figures are a research snapshot, not a buy or sell recommendation.

What Xenon Pharmaceuticals Inc. does

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapeutics for neurological disorders. The company currently generates no product revenue and relies on capital raises and potential future milestone or royalty payments from collaborative research and development agreements to fund its operations.

Products and services

  • The company is primarily developing azetukalner, an investigational small-molecule product candidate currently in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder, and bipolar depression.

Customer types

Healthcare providers and patients (potential future).

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on various third-party organizations to conduct pre-clinical and clinical studies and to manufacture drug products, APIs, and raw materials. Source

Business strengths to evaluate

  • Advanced clinical-stage pipeline led by azetukalner Source

Business risks and research considerations

  • History of significant losses and dependence on future capital raises Source
  • Substantial dependence on the successful development and regulatory approval of azetukalner Source
  • Reliance on third-party manufacturers and clinical research organizations Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

XENE financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 35.90
Market capitalization:
3.47B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -409.2M
Free cash flow:
USD -279.92M
Cash:
USD 119.53M
Total debt:
USD 6.42M
EPS:
USD -4.74

What stands out

  • Reported year-over-year revenue growth is -100.0%.
  • Free cash flow is USD -279.92M, negative for the stored period.
  • The balance sheet shows USD 119.53M of cash versus USD 6.42M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 113.11M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for XENE

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • What is driving XENE's revenue decline, and does the latest filing suggest the weakness is temporary or structural?
  • How long can XENE fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is XENE likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for XENE to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of XENE's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research XENE

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.